Jonathan Anderman
General Counsel bei COMPASS THERAPEUTICS, INC.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Thomas Schuetz | M | 63 | 10 Jahre | |
| Carl Gordon | M | 59 | 9 Jahre | |
| James Boylan | M | 57 | 2 Jahre | |
| Maria Freire | M | 69 | 3 Jahre | |
| Mary Gray | M | 71 | 2 Jahre | |
| Ellen Chiniara | F | 65 | 2 Jahre | |
| Phil Ferneau | M | 62 | 9 Jahre | |
| Richard Lindahl | M | 70 | 1 Jahre | |
| Anna Gifford | F | - | 3 Jahre | |
| Minori Rosales | M | 61 | 1 Jahre | |
| Rachid Izzar | M | - | 3 Jahre | |
| Robert Kerrey | M | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 Jahre |
| Michael McDonnell | M | 60 | 4 Jahre | |
| Patrick Hugh Conway | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 Jahre |
| Ian Chia | M | - | 6 Jahre | |
| Neil Lerner | M | 56 | 4 Jahre | |
| Jay Skyler | M | 77 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 Jahre |
| Karin Herrera | F | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Vered Bisker-Leib | M | 53 | 7 Jahre | |
| Jeffrey Capello | M | 69 | 3 Jahre | |
| Brett Ilan Kaplan | M | 50 | 2 Jahre | |
| Julie Sunderland | F | 51 | 2 Jahre | |
| Miranda Toledano | F | 47 | 1 Jahre | |
| Trevor Anthony Mill | M | 53 | 9 Jahre | |
| Stephen P. Squinto | M | 67 | 7 Jahre | |
| Robert W. Pangia | M | 72 | 24 Jahre | |
| William Jones | M | 68 | 2 Jahre | |
| David Wurzer | M | 65 | - | |
| Lynn Schenk | F | 79 | 25 Jahre | |
| Daniel Karp | M | 46 | 2 Jahre | |
| Philipp Von Rosenstiel | M | - | 6 Jahre | |
| Charbel Haber | M | - | 3 Jahre | |
| Stacy Lindborg | M | 53 | 8 Jahre | |
| Steve Doares | M | - | 10 Jahre | |
| Thane Wettig | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | - |
| Michael Berg | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 2 Jahre |
| F. Edmondson | M | 58 | 6 Jahre | |
| Stephanie Dyson | F | - | - | |
| Susan Kalled | M | - | 1 Jahre | |
| Ferenc Tracik | M | 60 | 3 Jahre | |
| Michael Mano | M | 47 | 2 Jahre | |
| Anirvan Ghosh | M | 60 | 3 Jahre | |
| Mark Hernon | M | - | 4 Jahre | |
| Mahalakshmi Radhakrishnan | M | - | 4 Jahre | |
| Mario Corso | M | - | - | |
| Ralph Kern | M | 67 | 5 Jahre | |
| John Yee | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 Jahre |
| Suzanne E. Murray | F | 49 | - | |
| Samantha Haeberlein | M | - | 5 Jahre | |
| Wildon Farwell | M | 49 | - | |
| Richard Rudick | M | 73 | 6 Jahre | |
| Christopher Henderson | M | - | 6 Jahre | |
| David Caouette | M | - | - | |
| Owen Hughes | M | 49 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 4 Jahre |
| David Green | M | 61 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 Jahre |
| James Rosenthal | M | 70 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 3 Jahre |
| Samantha Vieira | F | - | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 57 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Jonathan Anderman
- Persönliches Netzwerk
